Kenya is set to get its first dedicated pharmaceutical and life sciences manufacturing hub after Apifa Biotech secured grant funding from Swedfund International, Sweden's development finance institution. The proposed Biopharma Life Sciences Park at Konza Technopolis marks a significant step towards reducing Kenya's dependence on imported medicines and strengthening local healthcare manufacturing capacity. The project is a public-private partnership between Apifa Biotech and the Technopolis Development Authority.

The National Treasury approved the partnership in April 2026 to proceed to the development phase. A consortium comprising global real estate and investment advisory firm Jones Lang LaSalle (JLL) and healthcare research and analytics company IQVIA was selected to carry out the feasibility study. The study will bring expertise in life sciences strategy, infrastructure development, and investment planning.

Swedfund's grant will fund the technical and commercial assessments needed to establish the project's viability and lay the groundwork for attracting long-term private investment. Elsa Ekblom, Health Sector Lead, Project Accelerator at Swedfund, said the funding commitment will help advance the necessary groundwork and create a clear pathway toward maximizing national development outcomes.

Technopolis Development Authority Chief Executive Officer John Paul Okwiri said the park would transform Konza into a destination for pharmaceutical manufacturing and biotechnology innovation. The Biopharma Life Sciences Park will position Konza as an emerging centre for life sciences and pharmaceutical manufacturing, helping Kenya move from importing most of its medicines to producing them locally.

The proposed park will be designed, developed, and financed by Apifa Biotech, and is intended to create a collaborative environment for pharmaceutical manufacturers, researchers, investors, and technology enterprises. Apifa Biotech Board Chairman Dr. Gerald Macharia and Chief Executive Officer Dr. Keter reaffirmed the company's commitment to the project, expressing excitement about the milestone.

The initiative aligns with the African Union's target of meeting 60% of Africa's health product needs through local production by 2040, as well as Kenya's own policy goal of sourcing at least half of its essential health products domestically. The JLL-IQVIA findings are expected to shape the project's technical requirements, commercial structure, and implementation roadmap.

With the feasibility study now underway, the project is expected to create a world-class Biopharma Life Sciences manufacturing hub in Kenya for the East African Community region. The development is a significant step towards strengthening Kenya's healthcare manufacturing capacity and reducing its dependence on imported medicines.

Key points

  • The project is a public-private partnership between Apifa Biotech and the Technopolis Development Authority.
  • The proposed park will create a collaborative environment for pharmaceutical manufacturers, researchers, investors, and technology enterprises.
  • The initiative aligns with the African Union's target of meeting 60% of Africa's health product needs through local production by 2040.

Reporting sources

Share this story

Written by

SaharaWire Newsroom
SaharaWire

Reporting for SaharaWire from the Nairobi bureau.